Eli Lilly Invests $1.8 Billion to Expand Drug Production in Ireland

The investment will boost manufacturing of Alzheimer's, weight-loss, and diabetes treatments at facilities in Limerick and Kinsale.

Eli Lilly's $1.8 billion investment will expand production at two sites in Ireland to meet demand for its Alzheimer's, weight-loss, and diabetes drugs.
The Limerick facility will receive $1 billion to produce active ingredients for Alzheimer's drugs, including the newly approved Kisunla.
An additional $800 million will be spent on expanding the Kinsale site, which has been manufacturing obesity and diabetes treatments since last year.
The investments are part of Lilly's broader $20 billion commitment to enhancing manufacturing capabilities in the U.S. and Europe since 2020.
Lilly's key obesity drug Zepbound and diabetes injection Mounjaro have seen demand outstrip supply, prompting significant production increases.